{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:47:20Z","timestamp":1759160840573,"version":"3.37.3"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"DOI":"10.1007\/s11356-022-22661-1","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T11:03:03Z","timestamp":1662375783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current clinical status of new COVID-19 vaccines and immunotherapy"],"prefix":"10.1007","author":[{"given":"Diksha","family":"Nagpal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakti","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9502-2901","authenticated-orcid":false,"given":"Himanshu","family":"Kathuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"22661_CR1","unstructured":"Abhishek S, Mukesh T, Sharma LK, Chandra K (2020) Designing a multi-epitope peptide based vaccine against SARSCoV-2. Sci Rep 10:16219. https:\/\/doi.org\/10.1038%2Fs41598-020-73371-y"},{"key":"22661_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa2033130","volume":"384","author":"JD Lundgren","year":"2021","unstructured":"ACTIV-3\/TICO LY-CoV555 Study Group, Lundgren JD, Grund B et al (2021) A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 384:905\u2013914. https:\/\/doi.org\/10.1056\/NEJMoa2033130","journal-title":"N Engl J Med"},{"key":"22661_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41422-021-00590-x","volume":"32","author":"J Ai","year":"2022","unstructured":"Ai J, Zhang H, Zhang Q et al (2022) Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern. Cell Res 32:103\u2013106. https:\/\/doi.org\/10.1038\/s41422-021-00590-x","journal-title":"Cell Res"},{"key":"22661_CR4","doi-asserted-by":"publisher","first-page":"68071","DOI":"10.1007\/s11356-021-16809-8","volume":"28","author":"R Akter","year":"2021","unstructured":"Akter R, Rahman MH, Bhattacharya T et al (2021) Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. Environ Sci Pollut Res 28:68071\u201368089. https:\/\/doi.org\/10.1007\/s11356-021-16809-8","journal-title":"Environ Sci Pollut Res"},{"key":"22661_CR5","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1002\/jmv.27214","volume":"93","author":"QA Al Khames Aga","year":"2021","unstructured":"Al Khames Aga QA, Alkhaffaf WH, Hatem TH et al (2021) Safety of COVID-19 vaccines. J Med Virol 93:6588\u20136594. https:\/\/doi.org\/10.1002\/jmv.27214","journal-title":"J Med Virol"},{"key":"22661_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2021.04.019","volume":"88","author":"F Angeli","year":"2021","unstructured":"Angeli F, Spanevello A, Reboldi G et al (2021) SARS-CoV-2 vaccines: lights and shadows. Eur J Intern Med 88:1\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2021.04.019","journal-title":"Eur J Intern Med"},{"key":"22661_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jointm.2021.01.002","volume":"1","author":"D Annane","year":"2021","unstructured":"Annane D (2021) Corticosteroids for COVID-19. J Intensive Med 1:14\u201325. https:\/\/doi.org\/10.1016\/j.jointm.2021.01.002","journal-title":"J Intensive Med"},{"key":"22661_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12199-020-00904-2\/TABLES\/5","volume":"25","author":"K Azuma","year":"2020","unstructured":"Azuma K, Yanagi U, Kagi N et al (2020) Environmental factors involved in SARS-CoV-2 transmission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control. Environ Health Prev Med 25:1\u201316. https:\/\/doi.org\/10.1186\/S12199-020-00904-2\/TABLES\/5","journal-title":"Environ Health Prev Med"},{"key":"22661_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/nejmoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/nejmoa2035389","journal-title":"N Engl J Med"},{"key":"22661_CR10","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/nejmoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med 383:1813\u20131826. https:\/\/doi.org\/10.1056\/nejmoa2007764","journal-title":"N Engl J Med"},{"key":"22661_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/IDR.S288877","volume":"14","author":"TM Belete","year":"2021","unstructured":"Belete TM (2021) Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist 14:151\u2013161. https:\/\/doi.org\/10.2147\/IDR.S288877","journal-title":"Infect Drug Resist"},{"key":"22661_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijmr.IJMR_4165_20","volume":"153","author":"R Bhatia","year":"2021","unstructured":"Bhatia R (2021) The quest continues for perfect COVID-19 vaccine. Indian J Med Res 153:1\u20136. https:\/\/doi.org\/10.4103\/ijmr.IJMR_4165_20","journal-title":"Indian J Med Res"},{"key":"22661_CR13","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1021\/acsbiomaterials.1c00318","volume":"7","author":"Elham Bidram","year":"2021","unstructured":"Bidram E, Esameili Y, Amini A et al (2021) Nanobased platforms for diagnosis and treatment of COVID-19: from benchtop to bedside. ACS Biomater Sci Eng 7:2150\u20132176. https:\/\/doi.org\/10.1021\/acsbiomaterials.1c00318","journal-title":"ACS Biomater Sci Eng"},{"key":"22661_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/S10311-021-01187-X","volume":"19","author":"J Biryukov","year":"2021","unstructured":"Biryukov J, Boydston JA, Dunning RA et al (2021) SARS-CoV-2 is rapidly inactivated at high temperature. Environ Chem Lett 19:1773. https:\/\/doi.org\/10.1007\/S10311-021-01187-X","journal-title":"Environ Chem Lett"},{"key":"22661_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.15585\/MMWR.MM7011E3","volume":"70","author":"A Britton","year":"2021","unstructured":"Britton A, Slifka KMJ, Edens C et al (2021) Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks \u2014 Connecticut, December 2020\u2013February 2021. Morb Mortal Wkly Rep 70:396. https:\/\/doi.org\/10.15585\/MMWR.MM7011E3","journal-title":"Morb Mortal Wkly Rep"},{"key":"22661_CR16","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/S0140-6736(20)32156-5","volume":"396","author":"SP Buchbinder","year":"2020","unstructured":"Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L (2020) Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet 396:e68\u2013e69. https:\/\/doi.org\/10.1016\/S0140-6736(20)32156-5","journal-title":"Lancet"},{"key":"22661_CR17","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/s2213-2600(21)00559-2","volume":"10","author":"TK Burki","year":"2022","unstructured":"Burki TK (2022) Omicron variant and booster COVID-19 vaccines. Lancet Respir Med 10:e17. https:\/\/doi.org\/10.1016\/s2213-2600(21)00559-2","journal-title":"Lancet Respir Med"},{"key":"22661_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02853-4","author":"E Callaway","year":"2021","unstructured":"Callaway E (2021a) Mix-and-match COVID vaccines ace the effectiveness test. Nature. https:\/\/doi.org\/10.1038\/d41586-021-02853-4","journal-title":"Nature"},{"key":"22661_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway E (2021b) Heavily mutated Omicron variant puts scientists on alert. Nature 600:21. https:\/\/doi.org\/10.1038\/d41586-021-03552-w","journal-title":"Nature"},{"key":"22661_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/d41586-021-01359-3","volume":"593","author":"E Callaway","year":"2021","unstructured":"Callaway E (2021c) Mix-and-match COVID vaccines trigger potent immune response. Nature 593:491. https:\/\/doi.org\/10.1038\/d41586-021-01359-3","journal-title":"Nature"},{"key":"22661_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/d41586-021-03614-z","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway E, Ledford H (2021) How bad is Omicron? What scientists know so far. Nature 600:197\u2013199. https:\/\/doi.org\/10.1038\/d41586-021-03614-z","journal-title":"Nature"},{"key":"22661_CR22","unstructured":"Cascella M, Rajnik M, Cuomo A et al (2020) Features, evaluation and treatment coronavirus (COVID-19). StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/"},{"key":"22661_CR23","unstructured":"CDC (2021) Understanding viral vector CVOID-19 vaccines. October 18, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/viralvector.html"},{"key":"22661_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/FPUBH.2021.626852\/BIBTEX","volume":"9","author":"AA Cerda","year":"2021","unstructured":"Cerda AA, Garc\u00eda LY (2021) Hesitation and refusal factors in individuals\u2019 decision-making processes regarding a coronavirus disease 2019 vaccination. Front Public Heal 9:229. https:\/\/doi.org\/10.3389\/FPUBH.2021.626852\/BIBTEX","journal-title":"Front Public Heal"},{"key":"22661_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4110\/in.2021.21.e5","volume":"21","author":"C Chakraborty","year":"2021","unstructured":"Chakraborty C, Sharma AR, Bhattacharya M et al (2021) Ongoing clinical trials of vaccines to fight against Covid-19 pandemic. Immune Netw 21:1\u201322. https:\/\/doi.org\/10.4110\/in.2021.21.e5","journal-title":"Immune Netw"},{"key":"22661_CR26","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"VP Chavda","year":"2021","unstructured":"Chavda VP, Vora LK, Pandya AK, Patravale VB (2021) Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today 26:2619\u20132636. https:\/\/doi.org\/10.1016\/j.drudis.2021.07.021","journal-title":"Drug Discov Today"},{"key":"22661_CR27","doi-asserted-by":"publisher","unstructured":"Chung YH, Beiss V, Fiering SN, Steinmetz NF (2020) Covid-19 vaccine frontrunners and their nanotechnology design. ACS Nano 14:12522\u201312537.\u00a0https:\/\/doi.org\/10.1021\/acsnano.0c07197","DOI":"10.1021\/acsnano.0c07197"},{"key":"22661_CR28","doi-asserted-by":"publisher","first-page":"138474","DOI":"10.1016\/J.SCITOTENV.2020.138474","volume":"729","author":"M Coccia","year":"2020","unstructured":"Coccia M (2020) Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to COVID. Sci Total Environ 729:138474. https:\/\/doi.org\/10.1016\/J.SCITOTENV.2020.138474","journal-title":"Sci Total Environ"},{"key":"22661_CR29","doi-asserted-by":"publisher","unstructured":"Coccia M (2021a) High health expenditures and low exposure of population to air pollution as critical factors that can reduce fatality rate in COVID-19 pandemic crisis: a global analysis. Environ Res 199:111339. https:\/\/doi.org\/10.1016\/j.envres.2021a.111339","DOI":"10.1016\/j.envres.2021a.111339"},{"key":"22661_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/encyclopedia1020036","volume":"1","author":"M Coccia","year":"2021","unstructured":"Coccia M (2021b) Pandemic prevention: lessons from COVID-19. Encyclopedia 1:433\u2013444. https:\/\/doi.org\/10.3390\/encyclopedia1020036","journal-title":"Encyclopedia"},{"key":"22661_CR31","doi-asserted-by":"publisher","unstructured":"Coccia M (2022a) COVID-19 pandemic over 2020 (with lockdowns) and 2021 (with vaccinations): similar effects for seasonality and environmental factors. Environ Res 208:. https:\/\/doi.org\/10.1016\/J.ENVRES.2022.112711","DOI":"10.1016\/J.ENVRES.2022.112711"},{"key":"22661_CR32","doi-asserted-by":"publisher","unstructured":"Coccia M (2022b) Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: a global analysis. Environ Res 204:112314. https:\/\/doi.org\/10.1016\/J.ENVRES.2021.112314","DOI":"10.1016\/J.ENVRES.2021.112314"},{"key":"22661_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/nejmc2119270","volume":"386","author":"S Collie","year":"2022","unstructured":"Collie S, Champion J, Moultrie H et al (2022) Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med 386:494\u2013496. https:\/\/doi.org\/10.1056\/nejmc2119270","journal-title":"N Engl J Med"},{"key":"22661_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00696-4","author":"J Croda","year":"2022","unstructured":"Croda J, Ranzani OT (2022) Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00696-4","journal-title":"Lancet Infect Dis"},{"key":"22661_CR35","doi-asserted-by":"publisher","unstructured":"Cullis PR, Hope MJ (2017) Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25:1467\u20131475.\u00a0https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.013","DOI":"10.1016\/j.ymthe.2017.03.013"},{"key":"22661_CR36","doi-asserted-by":"publisher","unstructured":"Dan JM, Mateus J, Kato Y et al (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371(6529). https:\/\/doi.org\/10.1126\/science.abf4063","DOI":"10.1126\/science.abf4063"},{"key":"22661_CR37","unstructured":"Daniela S, Nigel C (2021) COVID-19 vaccine platforms - the Melbourne Vaccine Education Centre (MVEC). https:\/\/mvec.mcri.edu.au\/references\/covid-19-vaccine-platforms\/. Accessed 13 Jul 2022"},{"key":"22661_CR38","doi-asserted-by":"publisher","unstructured":"de Queiroz NMGP, Marinho FV, Chagas MA et al (2020) Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes Infect 22:515\u2013524.\u00a0https:\/\/doi.org\/10.1016\/j.micinf.2020.09.004","DOI":"10.1016\/j.micinf.2020.09.004"},{"key":"22661_CR39","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41587-021-01140-x","volume":"39","author":"L DeFrancesco","year":"2021","unstructured":"DeFrancesco L (2021) Preparing for the next plague. Nat Biotechnol 39:1491\u20131496. https:\/\/doi.org\/10.1038\/s41587-021-01140-x","journal-title":"Nat Biotechnol"},{"key":"22661_CR40","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","volume":"39","author":"A Dey","year":"2021","unstructured":"Dey A, Chozhavel Rajanathan TM, Chandra H et al (2021) Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. Vaccine 39:4108\u20134116. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.098","journal-title":"Vaccine"},{"key":"22661_CR41","doi-asserted-by":"publisher","first-page":"106204","DOI":"10.1016\/j.ijsu.2021.106204","volume":"97","author":"M Dhawan","year":"2022","unstructured":"Dhawan M, Priyanka PM et al (2022) Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks. Int J Surg 97:106204\u2013106204. https:\/\/doi.org\/10.1016\/j.ijsu.2021.106204","journal-title":"Int J Surg"},{"key":"22661_CR42","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C et al (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 117:9490\u20139496. https:\/\/doi.org\/10.1073\/pnas.2004168117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"22661_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/nejmoa2116185","volume":"386","author":"LM Dunkle","year":"2022","unstructured":"Dunkle LM, Kotloff KL, Gay CL et al (2022) Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med 386:531\u2013543. https:\/\/doi.org\/10.1056\/nejmoa2116185","journal-title":"N Engl J Med"},{"key":"22661_CR44","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/jcp.30076","volume":"236","author":"A Esmaeilzadeh","year":"2021","unstructured":"Esmaeilzadeh A, Elahi R (2021) Immunobiology and immunotherapy of COVID-19: a clinically updated overview. J Cell Physiol 236:2519\u20132543. https:\/\/doi.org\/10.1002\/jcp.30076","journal-title":"J Cell Physiol"},{"key":"22661_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijbiomac.2021.08.076","volume":"188","author":"H Fathizadeh","year":"2021","unstructured":"Fathizadeh H, Afshar S, Masoudi MR et al (2021) SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review. Int J Biol Macromol 188:740\u2013750. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.08.076","journal-title":"Int J Biol Macromol"},{"key":"22661_CR46","unstructured":"FDA (2021) FDA In Brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. In: FDA Br. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data. Acsessed 8 Feb 2022"},{"key":"22661_CR47","unstructured":"FDA - Food and Drug Adminstration (2021) Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. In: FDA News Release. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised. Accessed 8 Feb 2022"},{"key":"22661_CR48","unstructured":"FDA News Release (2021) FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. In: Food Drug Adm. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age"},{"key":"22661_CR49","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s40267-021-00869-4","volume":"37","author":"C Fenton","year":"2021","unstructured":"Fenton C, Lamb YN (2021) COVID-19: state of the vaccination. Drugs Ther Perspect 37:508\u2013518. https:\/\/doi.org\/10.1007\/s40267-021-00869-4","journal-title":"Drugs Ther Perspect"},{"key":"22661_CR50","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","volume":"62","author":"S Ferrari","year":"2021","unstructured":"Ferrari S, Caprioli C, Weber A et al (2021) Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 62:1490\u20131496. https:\/\/doi.org\/10.1080\/10428194.2021.1872070","journal-title":"Leuk Lymphoma"},{"key":"22661_CR51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.healthpol.2021.03.013","volume":"125","author":"R Forman","year":"2021","unstructured":"Forman R, Shah S, Jeurissen P et al (2021) COVID-19 vaccine challenges: what have we learned so far and what remains to be done? Health Policy (New York) 125:553\u2013567. https:\/\/doi.org\/10.1016\/j.healthpol.2021.03.013","journal-title":"Health Policy (New York)"},{"key":"22661_CR52","doi-asserted-by":"publisher","unstructured":"Forni G, Mantovani A, Forni G et al (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28:626\u2013639. https:\/\/doi.org\/10.1038\/s41418-020-00720-9","DOI":"10.1038\/s41418-020-00720-9"},{"key":"22661_CR53","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1016\/j.vaccine.2021.07.068","volume":"39","author":"GP Georgiadis","year":"2021","unstructured":"Georgiadis GP, Georgiadis MC (2021) Optimal planning of the COVID-19 vaccine supply chain. Vaccine 39:5302\u20135312. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.068","journal-title":"Vaccine"},{"key":"22661_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/a-1296-7935","volume":"71","author":"M Ghasemnejad-Berenji","year":"2021","unstructured":"Ghasemnejad-Berenji M, Pashapour S (2021) Favipiravir and COVID-19: a simplified summary. Drug Res (Stuttg) 71:166\u2013170. https:\/\/doi.org\/10.1055\/a-1296-7935","journal-title":"Drug Res (Stuttg)"},{"key":"22661_CR55","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/phe\/phab018","volume":"14","author":"A Giubilini","year":"2021","unstructured":"Giubilini A, Minerva F, Schuklenk U, Savulescu J (2021) The \u2018ethical\u2019 COVID-19 vaccine is the one that preserves lives: religious and moral beliefs on the COVID-19 vaccine. Public Health Ethics 14:242\u2013255. https:\/\/doi.org\/10.1093\/phe\/phab018","journal-title":"Public Health Ethics"},{"key":"22661_CR56","doi-asserted-by":"publisher","unstructured":"Gordon CJ, Tchesnokov EP, Schinazi RF, G\u00f6tte M (2021) Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem 297(1):100770. https:\/\/doi.org\/10.1016\/j.jbc.2021.100770","DOI":"10.1016\/j.jbc.2021.100770"},{"key":"22661_CR57","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1126\/science.abl8487","volume":"374","author":"RK Gupta","year":"2021","unstructured":"Gupta RK, Topol EJ (2021) COVID-19 vaccine breakthrough infections. Science (80- ) 374:1561\u20131562. https:\/\/doi.org\/10.1126\/science.abl8487","journal-title":"Science (80- )"},{"key":"22661_CR58","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1016\/j.vaccine.2020.07.003","volume":"38","author":"A Hashemzadeh","year":"2020","unstructured":"Hashemzadeh A, Avan A, Ferns GA, Khazaei M (2020) Vaccines based on virus-like nano-particles for use against Middle East respiratory syndrome (MERS) coronavirus. Vaccine 38:5742\u20135746. https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.003","journal-title":"Vaccine"},{"key":"22661_CR59","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan AO, Kafai NM, Dmitriev IP et al (2020) A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183:169-184.e13. https:\/\/doi.org\/10.1016\/j.cell.2020.08.026","journal-title":"Cell"},{"key":"22661_CR60","doi-asserted-by":"crossref","unstructured":"He Q, Mao Q, Zhang J et al (2021) COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol 12:1196.\u00a0https:\/\/doi.org\/10.3389%2Ffimmu.2021.669339","DOI":"10.3389\/fimmu.2021.669339"},{"key":"22661_CR61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41575-020-0295-7","volume":"17","author":"J Hindson","year":"2020","unstructured":"Hindson J (2020) COVID-19: faecal\u2013oral transmission? Nat Rev Gastroenterol Hepatol 17:259. https:\/\/doi.org\/10.1038\/s41575-020-0295-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"22661_CR62","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann M, Kr\u00fcger N, Schulz S et al (2022) The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 185:447-456.e11. https:\/\/doi.org\/10.1016\/j.cell.2021.12.032","journal-title":"Cell"},{"key":"22661_CR63","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/08820139.2021.1904977","volume":"50","author":"K Hofman","year":"2021","unstructured":"Hofman K, Shenoy GN, Chak V, Balu-Iyer SV (2021) Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Immunol Invest 50:743\u2013779. https:\/\/doi.org\/10.1080\/08820139.2021.1904977","journal-title":"Immunol Invest"},{"key":"22661_CR64","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14760584.2020.1874928","volume":"19","author":"MK Hossain","year":"2020","unstructured":"Hossain MK, Ahmed T, Bhusal P et al (2020) Microneedle systems for vaccine delivery: the story so far. Expert Rev Vaccines 19:1153\u20131166. https:\/\/doi.org\/10.1080\/14760584.2020.1874928","journal-title":"Expert Rev Vaccines"},{"key":"22661_CR65","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(21)00528-6","volume":"397","author":"IFN Hung","year":"2021","unstructured":"Hung IFN, Poland GA (2021) Single-dose Oxford\u2013AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet 397:854\u2013855. https:\/\/doi.org\/10.1016\/S0140-6736(21)00528-6","journal-title":"Lancet"},{"key":"22661_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","volume":"29","author":"YC Hwang","year":"2022","unstructured":"Hwang YC, Lu RM, Su SC et al (2022) Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci 29:1. https:\/\/doi.org\/10.1186\/s12929-021-00784-w","journal-title":"J Biomed Sci"},{"key":"22661_CR67","doi-asserted-by":"publisher","unstructured":"Ikegame S, Siddiquey MNA, Hung CT et al (2021) Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun 12:4598. https:\/\/doi.org\/10.1038\/s41467-021-24909-9","DOI":"10.1038\/s41467-021-24909-9"},{"key":"22661_CR68","doi-asserted-by":"publisher","unstructured":"Irfan M, Ahmad M, Fareed Z et al (2021) On the indirect environmental outcomes of COVID-19: short-term revival with futuristic long-term implications. 32(6):1271\u2013128. https:\/\/doi.org\/10.1080\/09603123.2021.1874888","DOI":"10.1080\/09603123.2021.1874888"},{"key":"22661_CR69","doi-asserted-by":"publisher","unstructured":"Islam N, Sheils NE, Jarvis MS, Cohen K (2022) Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun 13(1):2377. https:\/\/doi.org\/10.1038\/s41467-022-30059-3","DOI":"10.1038\/s41467-022-30059-3"},{"key":"22661_CR70","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S1473-3099(21)00020-7","volume":"21","author":"PL Iversen","year":"2021","unstructured":"Iversen PL, Bavari S (2021) Inactivated COVID-19 vaccines to make a global impact. Lancet Infect Dis 21:746\u2013748. https:\/\/doi.org\/10.1016\/S1473-3099(21)00020-7","journal-title":"Lancet Infect Dis"},{"key":"22661_CR71","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/nejmoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG et al (2020) An mRNA vaccine against sARS-CoV-2 \u2014 preliminary report. N Engl J Med 383:1920\u20131931. https:\/\/doi.org\/10.1056\/nejmoa2022483","journal-title":"N Engl J Med"},{"key":"22661_CR72","doi-asserted-by":"publisher","first-page":"e1003953","DOI":"10.1371\/journal.pmed.1003953","volume":"19","author":"P Jin","year":"2022","unstructured":"Jin P, Guo X, Chen W et al (2022) Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia\/ZF2001): a randomized, observer-blinded, placebo-controlled trial. PLOS Med 19:e1003953. https:\/\/doi.org\/10.1371\/journal.pmed.1003953","journal-title":"PLOS Med"},{"key":"22661_CR73","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/infdis\/jiab263","volume":"224","author":"S Joffe","year":"2021","unstructured":"Joffe S, Babiker A, Ellenberg SS et al (2021) Data and safety monitoring of COVID-19 vaccine clinical trials. J Infect Dis 224:1995\u20132000. https:\/\/doi.org\/10.1093\/infdis\/jiab263","journal-title":"J Infect Dis"},{"key":"22661_CR74","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"I Jones","year":"2021","unstructured":"Jones I, Roy P (2021) Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 397:642\u2013643.\u00a0https:\/\/doi.org\/10.1016\/s0140-6736(21)00191-4","journal-title":"Lancet"},{"key":"22661_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S42399-020-00498-4","volume":"2","author":"R Karia","year":"2020","unstructured":"Karia R, Gupta I, Khandait H et al (2020) COVID-19 and its modes of transmission. Sn Compr Clin Med 2:1. https:\/\/doi.org\/10.1007\/S42399-020-00498-4","journal-title":"Sn Compr Clin Med"},{"key":"22661_CR76","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","volume":"398","author":"SSA Karim","year":"2021","unstructured":"Karim SSA, Karim QA (2021) Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398:2126\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(21)02758-6","journal-title":"Lancet"},{"key":"22661_CR77","doi-asserted-by":"publisher","first-page":"64951","DOI":"10.1007\/s11356-021-16654-9","volume":"28","author":"C Karthika","year":"2021","unstructured":"Karthika C, Swathy Krishna R, Rahman MH et al (2021) COVID-19, the firestone in 21st century: a review on coronavirus disease and its clinical perspectives. Environ Sci Pollut Res 28:64951\u201364966. https:\/\/doi.org\/10.1007\/s11356-021-16654-9","journal-title":"Environ Sci Pollut Res"},{"key":"22661_CR78","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3201\/eid2802.211834","volume":"28","author":"J Kertes","year":"2022","unstructured":"Kertes J, Gez SB, Saciuk Y et al (2022) Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel. Emerg Infect Dis 28:338\u2013346. https:\/\/doi.org\/10.3201\/eid2802.211834","journal-title":"Emerg Infect Dis"},{"key":"22661_CR79","doi-asserted-by":"publisher","unstructured":"Khan WH, Hashmi Z, Goel A et al (2021) COVID-19 pandemic and vaccines update on challenges and resolutions. Front Cell Infect Microbiol 11. https:\/\/doi.org\/10.3389\/fcimb.2021.690621","DOI":"10.3389\/fcimb.2021.690621"},{"key":"22661_CR80","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","volume":"399","author":"A Khobragade","year":"2022","unstructured":"Khobragade A, Bhate S, Ramaiah V et al (2022) Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet (London, England) 399:1313. https:\/\/doi.org\/10.1016\/S0140-6736(22)00151-9","journal-title":"Lancet (London, England)"},{"key":"22661_CR81","doi-asserted-by":"publisher","unstructured":"Kiem CT, Andronico A, Bosetti P et al (2021) Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France. Eurosurveillance 26. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.26.2100533","DOI":"10.2807\/1560-7917.ES.2021.26.26.2100533"},{"key":"22661_CR82","doi-asserted-by":"publisher","unstructured":"Kirubananthan L, Illuri R, Rajendran R, Chandrasekaran PR (2021) Mechanism and transmission routes of COVID-19. Environ Heal Manag Nov Coronavirus Dis pp 65\u201388. https:\/\/doi.org\/10.1016\/B978-0-323-85780-2.00013-5","DOI":"10.1016\/B978-0-323-85780-2.00013-5"},{"key":"22661_CR83","doi-asserted-by":"publisher","unstructured":"Kitazawa K, Deinhardt-Emmer S, Inomata T et al (2021) The transmission of SARS-CoV-2 infection on the ocular surface and prevention strategies. Cells 10(4):796. https:\/\/doi.org\/10.3390\/CELLS10040796","DOI":"10.3390\/CELLS10040796"},{"key":"22661_CR84","doi-asserted-by":"publisher","first-page":"110318","DOI":"10.1016\/j.celrep.2022.110318","volume":"38","author":"KM Konrath","year":"2022","unstructured":"Konrath KM, Liaw K, Wu Y et al (2022) Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Rep 38:110318. https:\/\/doi.org\/10.1016\/j.celrep.2022.110318","journal-title":"Cell Rep"},{"key":"22661_CR85","doi-asserted-by":"publisher","first-page":"e0260733","DOI":"10.1371\/journal.pone.0260733","volume":"17","author":"SK Korang","year":"2022","unstructured":"Korang SK, von Rohden E, Veroniki AA et al (2022) Vaccines to prevent COVID-19: a living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS ONE 17:e0260733. https:\/\/doi.org\/10.1371\/journal.pone.0260733","journal-title":"PLoS ONE"},{"key":"22661_CR86","doi-asserted-by":"publisher","unstructured":"Kowalzik F, Schreiner D, Jensen C et al (2021) Mrna-based vaccines. Vaccines 9(4):390. https:\/\/doi.org\/10.3390\/vaccines9040390","DOI":"10.3390\/vaccines9040390"},{"key":"22661_CR87","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.3389\/fimmu.2021.752227","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar S, \u00c7al\u0131\u015fkan DM, Janowski J et al (2021) Beyond vaccines: clinical status of prospective COVID-19 therapeutics. Front Immunol 12:4064. https:\/\/doi.org\/10.3389\/fimmu.2021.752227","journal-title":"Front Immunol"},{"key":"22661_CR88","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.7150\/IJBS.59170","volume":"17","author":"HF Kwok","year":"2021","unstructured":"Kwok HF (2021) Review of Covid-19 vaccine clinical trials - a puzzle with missing pieces. Int J Biol Sci 17:1461. https:\/\/doi.org\/10.7150\/IJBS.59170","journal-title":"Int J Biol Sci"},{"key":"22661_CR89","doi-asserted-by":"publisher","unstructured":"Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV et al (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6. https:\/\/doi.org\/10.1038\/s41541-021-00292-w","DOI":"10.1038\/s41541-021-00292-w"},{"key":"22661_CR90","doi-asserted-by":"publisher","first-page":"e009010","DOI":"10.1136\/bmjgh-2022-009010","volume":"7","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Abdool Karim SS, van Selm L et al (2022a) COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Glob Heal 7:e009010. https:\/\/doi.org\/10.1136\/bmjgh-2022-009010","journal-title":"BMJ Glob Heal"},{"key":"22661_CR91","doi-asserted-by":"publisher","first-page":"e009010","DOI":"10.1136\/BMJGH-2022-009010","volume":"7","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Karim SSA, van Selm L et al (2022b) COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Glob Health 7:e009010. https:\/\/doi.org\/10.1136\/BMJGH-2022-009010","journal-title":"BMJ Glob Health"},{"key":"22661_CR92","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","volume":"18","author":"WW Leitner","year":"1999","unstructured":"Leitner WW, Ying H, Restifo NP (1999) DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18:765\u2013777. https:\/\/doi.org\/10.1016\/S0264-410X(99)00271-6","journal-title":"Vaccine"},{"key":"22661_CR93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/d41586-021-00251-4","volume":"590","author":"D Lewis","year":"2021","unstructured":"Lewis D (2021a) COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? Nature 590:26\u201328. https:\/\/doi.org\/10.1038\/d41586-021-00251-4","journal-title":"Nature"},{"key":"22661_CR94","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/d41586-021-01805-2","volume":"595","author":"D Lewis","year":"2021","unstructured":"Lewis D (2021b) Mix-and-match COVID vaccines: the case is growing, but questions remain. Nature 595:344\u2013345. https:\/\/doi.org\/10.1038\/d41586-021-01805-2","journal-title":"Nature"},{"key":"22661_CR95","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","volume":"28","author":"J Li","year":"2022","unstructured":"Li J, Hou L, Guo X et al (2022a) Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med 28:401\u2013409. https:\/\/doi.org\/10.1038\/s41591-021-01677-z","journal-title":"Nat Med"},{"key":"22661_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00996-y","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, Wang H, Tian L et al (2022b) COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther 7:1\u201332. https:\/\/doi.org\/10.1038\/s41392-022-00996-y","journal-title":"Signal Transduct Target Ther"},{"key":"22661_CR97","doi-asserted-by":"publisher","unstructured":"Lin Z, Phyu WH, Phyu ZH, Mon TZ (2021) The role of steroids in the management of COVID-19 infection. Cureus 13(8):e16841. https:\/\/doi.org\/10.7759\/cureus.16841","DOI":"10.7759\/cureus.16841"},{"key":"22661_CR98","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/nejmoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C et al (2021) Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 385:585\u2013594. https:\/\/doi.org\/10.1056\/nejmoa2108891","journal-title":"N Engl J Med"},{"key":"22661_CR99","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1126\/science.abg9857","volume":"373","author":"FE Lund","year":"2021","unstructured":"Lund FE, Randall TD (2021) Scent of a vaccine intranasal vaccination should block SARS-CoV-2 transmission at the source. Science (80- ) 373:397\u2013399. https:\/\/doi.org\/10.1126\/science.abg9857","journal-title":"Science (80- )"},{"key":"22661_CR100","doi-asserted-by":"publisher","unstructured":"Lundstrom K (2020) Application of viral vectors for vaccine development with a special emphasis on COVID-19. Viruses 12(11):1324. https:\/\/doi.org\/10.3390\/v12111324","DOI":"10.3390\/v12111324"},{"key":"22661_CR101","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jpha.2021.09.001","volume":"11","author":"L Luo","year":"2021","unstructured":"Luo L, Qiu Q, Huang F et al (2021) Drug repurposing against coronavirus disease 2019 (COVID-19): a review. J Pharm Anal 11:683\u2013690. https:\/\/doi.org\/10.1016\/j.jpha.2021.09.001","journal-title":"J Pharm Anal"},{"key":"22661_CR102","doi-asserted-by":"publisher","unstructured":"Ma Y, Pei S, Shaman J et al (2020) Role of air temperature and humidity in the transmission of SARS-CoV-2 in the United States. medRxiv 1\u201324.\u00a0https:\/\/doi.org\/10.1101\/2020.11.13.20231472","DOI":"10.1101\/2020.11.13.20231472"},{"key":"22661_CR103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.addr.2021.01.002","volume":"171","author":"J Machhi","year":"2021","unstructured":"Machhi J, Shahjin F, Das S et al (2021) Nanocarrier vaccines for SARS-CoV-2. Adv Drug Deliv Rev 171:215\u2013239. https:\/\/doi.org\/10.1016\/j.addr.2021.01.002","journal-title":"Adv Drug Deliv Rev"},{"issue":"27","key":"22661_CR104","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41591-021-01459-7","volume":"278","author":"S Machingaidze","year":"2021","unstructured":"Machingaidze S, Wiysonge CS (2021) Understanding COVID-19 vaccine hesitancy. Nat Med 278(27):1338\u20131339. https:\/\/doi.org\/10.1038\/s41591-021-01459-7","journal-title":"Nat Med"},{"key":"22661_CR105","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.vaccine.2021.04.042","volume":"40","author":"CR MacIntyre","year":"2022","unstructured":"MacIntyre CR, Costantino V, Trent M (2022) Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine 40:2506\u20132513. https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.042","journal-title":"Vaccine"},{"key":"22661_CR106","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1071\/MA20013","volume":"41","author":"JS MacKenzie","year":"2020","unstructured":"MacKenzie JS, Smith DW (2020) COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don\u2019t. Microbiol Aust 41:45\u201350. https:\/\/doi.org\/10.1071\/MA20013","journal-title":"Microbiol Aust"},{"key":"22661_CR107","doi-asserted-by":"publisher","unstructured":"Magro G (2020) SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the \u2018culprit lesion\u2019 of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X 2.\u00a0https:\/\/doi.org\/10.1016\/j.cytox.2020.100029","DOI":"10.1016\/j.cytox.2020.100029"},{"key":"22661_CR108","doi-asserted-by":"publisher","unstructured":"Majumder J, Minko T (2021) Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J p 23. https:\/\/doi.org\/10.1208\/s12248-020-00532-2","DOI":"10.1208\/s12248-020-00532-2"},{"key":"22661_CR109","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","volume":"598","author":"S Mallapaty","year":"2021","unstructured":"Mallapaty S (2021) China\u2019s COVID vaccines have been crucial - now immunity is waning. Nature 598:398\u2013399. https:\/\/doi.org\/10.1038\/d41586-021-02796-w","journal-title":"Nature"},{"key":"22661_CR110","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/d41586-021-03830-7","volume":"601","author":"S Mallapaty","year":"2022","unstructured":"Mallapaty S (2022) Researchers fear growing COVID vaccine hesitancy in developing nations. Nature 601:174\u2013175. https:\/\/doi.org\/10.1038\/d41586-021-03830-7","journal-title":"Nature"},{"key":"22661_CR111","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/s0262-4079(22)00081-1","volume":"253","author":"M Marshall","year":"2022","unstructured":"Marshall M (2022) How can we end the pandemic? New Sci 253:12\u201315. https:\/\/doi.org\/10.1016\/s0262-4079(22)00081-1","journal-title":"New Sci"},{"key":"22661_CR112","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu E, Ritchie H, Ortiz-Ospina E et al (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 5:947\u2013953. https:\/\/doi.org\/10.1038\/s41562-021-01122-8","journal-title":"Nat Hum Behav"},{"key":"22661_CR113","unstructured":"McGinley L, Lena H. Sun (n.d.) FDA adds new warning on Johnson & Johnson vaccine related to rare autoimmune disorder. https:\/\/www.washingtonpost.com\/health\/2021\/07\/12\/johnson-and-johnson-warning\/. Accessed 8 Feb 2022"},{"key":"22661_CR114","doi-asserted-by":"publisher","unstructured":"Mei M, Tan X (2021) Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci 8:671263:. https:\/\/doi.org\/10.3389\/fmolb.2021.671263","DOI":"10.3389\/fmolb.2021.671263"},{"key":"22661_CR115","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.spc.2020.10.016","volume":"26","author":"M Mofijur","year":"2021","unstructured":"Mofijur M, Fattah IMR, Alam MA et al (2021) Impact of COVID-19 on the social, economic, environmental and energy domains: lessons learnt from a global pandemic. Sustain Prod Consum 26:343\u2013359. https:\/\/doi.org\/10.1016\/j.spc.2020.10.016","journal-title":"Sustain Prod Consum"},{"key":"22661_CR116","doi-asserted-by":"publisher","unstructured":"Mohapatra PR, Mishra B (2021) Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode. Lancet Infect Dis 21:599\u2013600.\u00a0https:\/\/doi.org\/10.1016\/S1473-3099(21)00045-1","DOI":"10.1016\/S1473-3099(21)00045-1"},{"key":"22661_CR117","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.eclinm.2021.101020","volume":"38","author":"T Momin","year":"2021","unstructured":"Momin T, Kansagra K, Patel H et al (2021) Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. eClinicalMedicine 38:101020. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101020","journal-title":"eClinicalMedicine"},{"key":"22661_CR118","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4103\/jfmpc.jfmpc_1139_21","volume":"11","author":"R Mondal","year":"2022","unstructured":"Mondal R, MishraPillai SJK, Sahoo M (2022) COVID 19 pandemic and biomedical waste management practices in healthcare system. J Fam Med Prim Care 11:439. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1139_21","journal-title":"J Fam Med Prim Care"},{"key":"22661_CR119","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.cellimm.2021.104398","volume":"367","author":"SM Monzavi","year":"2021","unstructured":"Monzavi SM, Naderi M, Ahmadbeigi N et al (2021) An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. Cell Immunol 367:104398. https:\/\/doi.org\/10.1016\/j.cellimm.2021.104398","journal-title":"Cell Immunol"},{"key":"22661_CR120","unstructured":"No Author (n.d.) Anti-SARS-CoV-2 Monoclonal Antibodies | COVID-19 treatment guidelines.\nIn: Natl. Institutes Heal. https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/anti-sars-cov-2-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/. Accessed 7 July 2022"},{"key":"22661_CR121","unstructured":"No Author (2020) Corticosteroids | COVID-19 treatment guidelines. In: News release. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 6 Jul 2022"},{"key":"22661_CR122","unstructured":"No Author (2021a) U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 | National Institutes of Health (NIH). https:\/\/www.nih.gov\/news-events\/news-releases\/us-clinical-trial-results-show-novavax-vaccine-safe-prevents-covid-19. Accessed 8 Feb 2022"},{"key":"22661_CR123","unstructured":"No Author (2022b) Valneva receives marketing authorization in europe for inactivated Whole-Virus COVID-19 Vaccine VLA2001 - Valneva. https:\/\/valneva.com\/press-release\/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001\/. Accessed 13 Jul 2022"},{"key":"22661_CR124","unstructured":"No Author (2022b) Premas biotech and oramed announce oral COVID-19 vaccine candidate that produces antibodies after a single dose. https:\/\/www.businesswire.com\/news\/home\/20210319005359\/en\/Premas-Biotech-and-Oramed-Announce-Oral-COVID-19-Vaccine-Candidate-That-Produces-Antibodies-After-a-Single-Dose. Accessed 8 Feb 2022"},{"key":"22661_CR125","doi-asserted-by":"publisher","unstructured":"Nooraei S, Bahrulolum H, Hoseini ZS et al (2021) Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 19(59). https:\/\/doi.org\/10.1186\/s12951-021-00806-7","DOI":"10.1186\/s12951-021-00806-7"},{"key":"22661_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173854","volume":"894","author":"S Noreen","year":"2021","unstructured":"Noreen S, Maqbool I, Madni A (2021) Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol 894:173854. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173854","journal-title":"Eur J Pharmacol"},{"key":"22661_CR127","unstructured":"Nurith A (2022a) Rethinking the 70% COVID vaccination goal. Plus: a map of global progress\u202f: Goats and Soda\u202f: NPR. https:\/\/www.npr.org\/sections\/goatsandsoda\/2022a\/03\/14\/1086474455\/the-goal-vaccinate-70-of-the-world-against-covid-scientists-are-proposing-a-rebo. Accessed 13 Jul 2022"},{"key":"22661_CR128","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1016\/j.vaccine.2021.08.018","volume":"39","author":"S Okamura","year":"2021","unstructured":"Okamura S, Ebina H (2021) Could live attenuated vaccines better control COVID-19? Vaccine 39:5719\u20135726. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.018","journal-title":"Vaccine"},{"key":"22661_CR129","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/JMV.27655","volume":"94","author":"SP Parida","year":"2022","unstructured":"Parida SP, Sahu DP, Singh AK et al (2022) Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol 94:2453\u20132459. https:\/\/doi.org\/10.1002\/JMV.27655","journal-title":"J Med Virol"},{"key":"22661_CR130","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","volume":"17","author":"JW Park","year":"2021","unstructured":"Park JW, Lagniton PNP, Liu Y, Xu RH (2021) Mrna vaccines for covid-19: what, why and how. Int J Biol Sci 17:1446\u20131460. https:\/\/doi.org\/10.7150\/ijbs.59233","journal-title":"Int J Biol Sci"},{"key":"22661_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.physrep.2021.02.001","volume":"913","author":"N Perra","year":"2021","unstructured":"Perra N (2021) Non-pharmaceutical interventions during the COVID-19 pandemic: a review. Phys Rep 913:1\u201352. https:\/\/doi.org\/10.1016\/j.physrep.2021.02.001","journal-title":"Phys Rep"},{"key":"22661_CR132","unstructured":"Pfizer (2021) Pfizer and BioNTech provide update on omicron variant. In: Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-provide-update-omicron-variant. Accessed 8 Feb 2022"},{"key":"22661_CR133","unstructured":"Pfizer Inc (2021) Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19. In: Pfizer Inc. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provide-us-government-10-million-treatment-courses"},{"key":"22661_CR134","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.13005\/BPJ\/2054","volume":"13","author":"D Purohit","year":"2020","unstructured":"Purohit D, Saini M, Pathak N et al (2020) COVID-19 \u201cthe pandemic\u201d: an update on the present status of the outbreak and possible treatment options. Biomed Pharmacol J 13:1791\u20131807. https:\/\/doi.org\/10.13005\/BPJ\/2054","journal-title":"Biomed Pharmacol J"},{"key":"22661_CR135","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2147\/OPTH.S295283","volume":"15","author":"JY Qu","year":"2021","unstructured":"Qu JY, Xie HT, Zhang MC (2021) Evidence of SARS-CoV-2 transmission through the ocular route. Clin Ophthalmol 15:687. https:\/\/doi.org\/10.2147\/OPTH.S295283","journal-title":"Clin Ophthalmol"},{"key":"22661_CR136","doi-asserted-by":"publisher","first-page":"e1003891","DOI":"10.1371\/journal.pmed.1003891","volume":"19","author":"KL Quinn","year":"2022","unstructured":"Quinn KL, Bell CM (2022) Pandemic health consequences: grasping the long COVID tail. PLoS Med 19:e1003891. https:\/\/doi.org\/10.1371\/journal.pmed.1003891","journal-title":"PLoS Med"},{"key":"22661_CR137","doi-asserted-by":"publisher","unstructured":"Raju R, Prajith V, Biatris PS, J SJUC (2021) Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials. Futur J Pharm Sci 7(67). https:\/\/doi.org\/10.1186\/s43094-021-00217-3","DOI":"10.1186\/s43094-021-00217-3"},{"key":"22661_CR138","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/jmv.27463","volume":"94","author":"R Rashedi","year":"2022","unstructured":"Rashedi R, Samieefar N, Masoumi N et al (2022) COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J Med Virol 94:1294\u20131299. https:\/\/doi.org\/10.1002\/jmv.27463","journal-title":"J Med Virol"},{"key":"22661_CR139","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/nnm-2020-0441","volume":"16","author":"H Rashidzadeh","year":"2021","unstructured":"Rashidzadeh H, Danafar H, Rahimi H et al (2021) Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives. Nanomedicine 16:497\u2013516. https:\/\/doi.org\/10.2217\/nnm-2020-0441","journal-title":"Nanomedicine"},{"key":"22661_CR140","doi-asserted-by":"publisher","first-page":"173751","DOI":"10.1016\/j.ejphar.2020.173751","volume":"892","author":"K Rawat","year":"2021","unstructured":"Rawat K, Kumari P, Saha L (2021) COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 892:173751. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173751","journal-title":"Eur J Pharmacol"},{"key":"22661_CR141","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4155\/tde-2016-0006","volume":"7","author":"AM Reichmuth","year":"2016","unstructured":"Reichmuth AM, Oberli MA, Jeklenec A et al (2016) mRNA vaccine delivery using lipid nanoparticles. Ther Deliv 7:319\u2013334. https:\/\/doi.org\/10.4155\/tde-2016-0006","journal-title":"Ther Deliv"},{"key":"22661_CR142","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0140-6736(21)02757-4","volume":"399","author":"CD Richardson","year":"2022","unstructured":"Richardson CD (2022) Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19. Lancet 399:3\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(21)02757-4","journal-title":"Lancet"},{"key":"22661_CR143","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","volume":"18","author":"M Robert-Guroff","year":"2007","unstructured":"Robert-Guroff M (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18:546\u2013556. https:\/\/doi.org\/10.1016\/j.copbio.2007.10.010","journal-title":"Curr Opin Biotechnol"},{"key":"22661_CR144","doi-asserted-by":"publisher","unstructured":"Robinson J (2021) Oral antiviral may cut risk of COVID-19 hospitalisation by nearly 90%, manufacturer claims. Pharm J 307(7955). https:\/\/doi.org\/10.1211\/pj.2021.1.114284","DOI":"10.1211\/pj.2021.1.114284"},{"key":"22661_CR145","doi-asserted-by":"publisher","unstructured":"Saavedra D, A\u00f1\u00e9-Kour\u00ed AL, S\u00e1nchez N et al (2020) An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing 17(34). https:\/\/doi.org\/10.1186\/s12979-020-00207-8","DOI":"10.1186\/s12979-020-00207-8"},{"key":"22661_CR146","doi-asserted-by":"publisher","unstructured":"Sanders B, Koldijk M, Schuitemaker H (2015) Inactivated viral vaccines. Vaccine Anal Strateg Princ Control 45\u201380.\u00a0https:\/\/doi.org\/10.1007\/978-3-662-45024-6_2","DOI":"10.1007\/978-3-662-45024-6_2"},{"key":"22661_CR147","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA et al (2021) mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm 601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586","journal-title":"Int J Pharm"},{"key":"22661_CR148","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","volume":"30","author":"C Schwarz","year":"1994","unstructured":"Schwarz C, Mehnert W, Lucks JS, M\u00fcller RH (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 30:83\u201396. https:\/\/doi.org\/10.1016\/0168-3659(94)90047-7","journal-title":"J Control Release"},{"key":"22661_CR149","doi-asserted-by":"publisher","unstructured":"Sekizawa Y, Hashimoto S, Denda K et al (2022) Association between COVID-19 vaccine hesitancy and generalized trust, depression, generalized anxiety, and fear of COVID-19. BMC Public Health 22(126).\u00a0https:\/\/doi.org\/10.1186\/s12889-021-12479-w","DOI":"10.1186\/s12889-021-12479-w"},{"key":"22661_CR150","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2217\/fvl-2021-0170","volume":"17","author":"M Shafaati","year":"2022","unstructured":"Shafaati M, Saidijam M, Soleimani M et al (2022) A brief review on DNA vaccines in the era of COVID-19. Future Virol 17:49\u201366. https:\/\/doi.org\/10.2217\/fvl-2021-0170","journal-title":"Future Virol"},{"key":"22661_CR151","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F et al (2020) Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA - J Am Med Assoc 323:1582\u20131589. https:\/\/doi.org\/10.1001\/jama.2020.4783","journal-title":"JAMA - J Am Med Assoc"},{"key":"22661_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/D41586-022-01602-5","author":"SM Sidik","year":"2022","unstructured":"Sidik SM (2022) New COVID drugs face delays as trials grow more difficult. Nature. https:\/\/doi.org\/10.1038\/D41586-022-01602-5","journal-title":"Nature"},{"key":"22661_CR153","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00251-021-01226-5","volume":"74","author":"K Singh","year":"2022","unstructured":"Singh K, Kumar S, Shastri S et al (2022) Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India. Immunogenetics 74:197\u2013206. https:\/\/doi.org\/10.1007\/s00251-021-01226-5","journal-title":"Immunogenetics"},{"key":"22661_CR154","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11046-020-00462-9","volume":"185","author":"G Song","year":"2020","unstructured":"Song G, Liang G, Liu W (2020) Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 185:599\u2013606. https:\/\/doi.org\/10.1007\/s11046-020-00462-9","journal-title":"Mycopathologia"},{"key":"22661_CR155","doi-asserted-by":"publisher","unstructured":"Ssentongo P, Ssentongo AE, Voleti N et al (2022) SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis 22(439). https:\/\/doi.org\/10.1186\/s12879-022-07418-y","DOI":"10.1186\/s12879-022-07418-y"},{"key":"22661_CR156","doi-asserted-by":"publisher","first-page":"e1009704","DOI":"10.1371\/journal.ppat.1009704","volume":"17","author":"SC Su","year":"2021","unstructured":"Su SC, Yang TJ, Yu PY et al (2021) Structure-guided antibody cocktail for prevention and treatment of COVID-19. PLoS Pathog 17:e1009704. https:\/\/doi.org\/10.1371\/journal.ppat.1009704","journal-title":"PLoS Pathog"},{"key":"22661_CR157","doi-asserted-by":"publisher","first-page":"14051","DOI":"10.3390\/molecules200814051","volume":"20","author":"S Szunerits","year":"2015","unstructured":"Szunerits S, Barras A, Khanal M et al (2015) Nanostructures for the inhibition of viral infections. Molecules 20:14051\u201314081.\u00a0https:\/\/doi.org\/10.3390\/molecules200814051","journal-title":"Molecules"},{"key":"22661_CR158","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2119407","author":"E Takashita","year":"2022","unstructured":"Takashita E, Kinoshita N, Yamayoshi S et al (2022) Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmc2119407","journal-title":"N Engl J Med"},{"issue":"21","key":"22661_CR159","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"216","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM et al (2021) (2021) Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 216(21):382\u2013393. https:\/\/doi.org\/10.1038\/s41577-021-00542-x","journal-title":"Nat Rev Immunol"},{"key":"22661_CR160","doi-asserted-by":"publisher","unstructured":"Tebas P, Yang SP, Boyer JD et al (2021) Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 100689. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100689","DOI":"10.1016\/j.eclinm.2020.100689"},{"key":"22661_CR161","doi-asserted-by":"publisher","first-page":"120686","DOI":"10.1016\/j.ijpharm.2021.120686","volume":"603","author":"M Tiboni","year":"2021","unstructured":"Tiboni M, Casettari L, Illum L (2021) Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines? Int J Pharm 603:120686. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120686","journal-title":"Int J Pharm"},{"key":"22661_CR162","doi-asserted-by":"publisher","unstructured":"Tong S, Su Y, Yu Y et al (2020) Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 56(3):06114. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106114","DOI":"10.1016\/j.ijantimicag.2020.106114"},{"key":"22661_CR163","doi-asserted-by":"publisher","unstructured":"Tuccori M, Ferraro S, Convertino I et al (2020) Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs 12(1):1854149. https:\/\/doi.org\/10.1080\/19420862.2020.1854149","DOI":"10.1080\/19420862.2020.1854149"},{"key":"22661_CR164","doi-asserted-by":"publisher","unstructured":"Uddin MN, Roni MA (2021) Challenges of storage and stability of mRNA-based covid-19 vaccines. Vaccines 9(9):1033. https:\/\/doi.org\/10.3390\/vaccines9091033","DOI":"10.3390\/vaccines9091033"},{"key":"22661_CR165","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3934\/publichealth.2021011","volume":"8","author":"S Umakanthan","year":"2021","unstructured":"Umakanthan S, Chattu VK, Ranade AV et al (2021) A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. AIMS Public Heal 8:137\u2013153. https:\/\/doi.org\/10.3934\/publichealth.2021011","journal-title":"AIMS Public Heal"},{"key":"22661_CR166","unstructured":"US FDA (2021) FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. In: Https:\/\/Www.Fda.Gov\/Drugs\/Drug-Safety-and-Availability\/Fda-Authorizes-Bamlanivimab-and-Etesevimab-Monoclonal-Antibody-Therapy-Post-Exposure-Prophylaxis"},{"key":"22661_CR167","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"D van Riel","year":"2020","unstructured":"van Riel D, de Wit E (2020) Next-generation vaccine platforms for COVID-19. Nat Mater 19:810\u2013812. https:\/\/doi.org\/10.1038\/s41563-020-0746-0","journal-title":"Nat Mater"},{"key":"22661_CR168","doi-asserted-by":"publisher","first-page":"105998","DOI":"10.1016\/j.ijantimicag.2020.105998","volume":"56","author":"N Vankadari","year":"2020","unstructured":"Vankadari N (2020) Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents 56:105998. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105998","journal-title":"Int J Antimicrob Agents"},{"key":"22661_CR169","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-021-04792-9","volume":"41","author":"T Velikova","year":"2021","unstructured":"Velikova T, Georgiev T (2021) SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int 41:509\u2013518. https:\/\/doi.org\/10.1007\/s00296-021-04792-9","journal-title":"Rheumatol Int"},{"key":"22661_CR170","doi-asserted-by":"publisher","first-page":"e7967","DOI":"10.5867\/medwave.2020.06.7966","volume":"20","author":"F Verdugo-Paiva","year":"2020","unstructured":"Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G (2020) Lopinavir-ritonavir para COVID-19: una revisi\u00f3n sistem\u00e1tica viva. Medwave 20:e7967. https:\/\/doi.org\/10.5867\/medwave.2020.06.7966","journal-title":"Medwave"},{"key":"22661_CR171","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fmolb.2021.604447","volume":"8","author":"K Vivekanandhan","year":"2021","unstructured":"Vivekanandhan K, Shanmugam P, Barabadi H et al (2021) Emerging therapeutic approaches to combat COVID-19: present status and future perspectives. Front Mol Biosci 8:55. https:\/\/doi.org\/10.3389\/fmolb.2021.604447","journal-title":"Front Mol Biosci"},{"key":"22661_CR172","doi-asserted-by":"publisher","unstructured":"Wang CC, Prather KA, Sznitman J et al (2021a) Airborne transmission of respiratory viruses. Science 373(6558). https:\/\/doi.org\/10.1126\/science.abd9149","DOI":"10.1126\/science.abd9149"},{"key":"22661_CR173","doi-asserted-by":"publisher","unstructured":"Wang Y, Chen X, Wang F et al (2021b) Value of anal swabs for SARS-COV-2 detection: a literature review. Int J Med Sci18(11):2389\u20132393. https:\/\/doi.org\/10.7150\/IJMS.59382","DOI":"10.7150\/IJMS.59382"},{"key":"22661_CR174","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","volume":"27","author":"BJ Ward","year":"2021","unstructured":"Ward BJ, Gobeil P, S\u00e9guin A et al (2021) Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med 27:1071\u20131078. https:\/\/doi.org\/10.1038\/s41591-021-01370-1","journal-title":"Nat Med"},{"key":"22661_CR175","doi-asserted-by":"publisher","unstructured":"Wei Q, Lin H, Wei RG, et al (2021) Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty 10(71). https:\/\/doi.org\/10.1186\/s40249-021-00857-w","DOI":"10.1186\/s40249-021-00857-w"},{"key":"22661_CR176","unstructured":"WHO (2021a) The Novavax vaccine against COVID-19: what you need to know. In: World Heal. Organ. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-novavax-vaccine-against-covid-19-what-you-need-to-know"},{"key":"22661_CR177","unstructured":"WHO (2021b) The Sinopharm COVID-19 vaccine: what you need to know. In: World Heal. Organ. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-sinopharm-covid-19-vaccine-what-you-need-to-know"},{"key":"22661_CR178","unstructured":"WHO (2022) Strategy to achieve global Covid-19 vaccination by mid-2022. Who 1\u201316. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/covid-19\/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf"},{"key":"22661_CR179","unstructured":"WHO 2020c (2019) Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza global influenza programme non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza. https:\/\/www.who.int\/publications\/i\/item\/non-pharmaceutical-public-health-measuresfor-mitigating-the-risk-and-impact-of-epidemic-and-pandemic-influenza. Accessed 8 Feb 2022"},{"key":"22661_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02783-1","author":"C Willyard","year":"2021","unstructured":"Willyard C (2021) How antiviral pill molnupiravir shot ahead in the COVID drug hunt. Nature. https:\/\/doi.org\/10.1038\/d41586-021-02783-1","journal-title":"Nature"},{"key":"22661_CR181","doi-asserted-by":"publisher","first-page":"139051","DOI":"10.1016\/j.scitotenv.2020.139051","volume":"729","author":"Y Wu","year":"2020","unstructured":"Wu Y, Jing W, Liu J et al (2020) Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries. Sci Total Environ 729:139051. https:\/\/doi.org\/10.1016\/j.scitotenv.2020.139051","journal-title":"Sci Total Environ"},{"key":"22661_CR182","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.15585\/mmwr.mm7043e2","volume":"70","author":"S Xu","year":"2021","unstructured":"Xu S, Huang R, Sy LS et al (2021) COVID-19 vaccination and non\u2013COVID-19 mortality risk \u2014 seven integrated health care organizations, United States, December 14, 2020\u2013July 31, 2021. MMWR Morb Mortal Wkly Rep 70:1520\u20131524. https:\/\/doi.org\/10.15585\/mmwr.mm7043e2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"22661_CR183","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1080\/21645515.2020.1820808","volume":"16","author":"T Yadav","year":"2020","unstructured":"Yadav T, Srivastava N, Mishra G et al (2020) Recombinant vaccines for COVID-19. Hum Vaccines Immunother 16:2905\u20132912. https:\/\/doi.org\/10.1080\/21645515.2020.1820808","journal-title":"Hum Vaccines Immunother"},{"key":"22661_CR184","doi-asserted-by":"publisher","first-page":"18885","DOI":"10.1002\/anie.202008319","volume":"59","author":"T Ye","year":"2020","unstructured":"Ye T, Zhong Z, Garc\u00eda-Sastre A et al (2020) Current status of COVID-19 (pre)clinical vaccine development. Angew Chemie - Int Ed 59:18885\u201318897. https:\/\/doi.org\/10.1002\/anie.202008319","journal-title":"Angew Chemie - Int Ed"},{"key":"22661_CR185","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c03252","author":"Y Yin","year":"2021","unstructured":"Yin Y, Su W, Zhang J et al (2021) Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19. ACS Nano. https:\/\/doi.org\/10.1021\/acsnano.1c03252","journal-title":"ACS Nano"},{"key":"22661_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-022-00375-5","volume":"8","author":"X Yu","year":"2022","unstructured":"Yu X, Wei D, Xu W et al (2022) Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discov 8:1\u20134. https:\/\/doi.org\/10.1038\/s41421-022-00375-5","journal-title":"Cell Discov"},{"key":"22661_CR187","doi-asserted-by":"publisher","unstructured":"Zeng B, Gao L, Zhou Q et al (2022) Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med 20. https:\/\/doi.org\/10.1186\/s12916-022-02397-y","DOI":"10.1186\/s12916-022-02397-y"},{"key":"22661_CR188","doi-asserted-by":"publisher","unstructured":"Zha L, Chang X, Zhao H et al (2021) Development of a vaccine against sars-cov-2 based on the receptor-binding domain displayed on virus-like particles. Vaccines 9. https:\/\/doi.org\/10.3390\/vaccines9040395","DOI":"10.3390\/vaccines9040395"},{"key":"22661_CR189","doi-asserted-by":"publisher","first-page":"115621","DOI":"10.1016\/j.envpol.2020.115621","volume":"267","author":"J Zhan","year":"2020","unstructured":"Zhan J, Liu QS, Sun Z et al (2020) Environmental impacts on the transmission and evolution of COVID-19 combing the knowledge of pathogenic respiratory coronaviruses. Environ Pollut 267:115621. https:\/\/doi.org\/10.1016\/j.envpol.2020.115621","journal-title":"Environ Pollut"},{"key":"22661_CR190","doi-asserted-by":"publisher","unstructured":"Zhang H, Bussmann J, Huhnke FH et al (2021) Together is BETTER: mRNA Co-encapsulation in lipoplexes is required to obtain ratiometric co-delivery and protein expression on the single cell level. Adv Sci 9. https:\/\/doi.org\/10.1002\/advs.202102072","DOI":"10.1002\/advs.202102072"},{"key":"22661_CR191","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1038\/s41598-021-83959-7","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Cunningham MH, Mediavilla JR et al (2021) Diagnosis, clinical characteristics, and outcomes of COVID-19 patients from a large healthcare system in northern New Jersey. Sci Rep 11:4389. https:\/\/doi.org\/10.1038\/s41598-021-83959-7","journal-title":"Sci Rep"},{"key":"22661_CR192","doi-asserted-by":"publisher","unstructured":"Zhenghui X, Moyle PM (2018) Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached Toll-Like Receptor Ligands. Bioconjug Chem 29(3):572\u2013586.\u00a0https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00478","DOI":"10.1021\/acs.bioconjchem.7b00478"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-22661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-022-22661-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-22661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T13:20:18Z","timestamp":1664976018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-022-22661-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":192,"alternative-id":["22661"],"URL":"https:\/\/doi.org\/10.1007\/s11356-022-22661-1","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"type":"print","value":"0944-1344"},{"type":"electronic","value":"1614-7499"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}